Replies to post #560222 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

I hear you.

It sounds like you would prefer a completely different trial altogether. Murcidencel has been investigated in three successful trials—only the P3 relied on an ECA. I recommend the pembrolizumab combo study at UCLA supported by the NIH and Merck. The interim survival data are astonishing so far at the midpoint of this study.

https://clinicaltrials.gov/ct2/show/NCT04201873

The combo research is briefly highlighted by Dr. Toms at timestamp 6:30:

The placebo group for the combo trial are all receiving murcidencel (DCVax-L) as if it were SoC already.






https://cancer.ucla.edu/research/ucla-brain-spore/research-projects

Murcidencel (DCVax-L) is discussed beginning at minute 40, to focus on Keytruda (pembrolizumab) plus DCVax in combo at UCLA, skip to minute 45:40

https://connect.uclahealth.org/2021/03/22/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020/




https://www.fda.gov/science-research/advancing-regulatory-science/fda-nih-joint-leadership-council-charter




The NIH is largely responsible for the development of the murcidencel cell-based platform technology as they have always supported and funded Liau’s research. The 20 consecutive years of NIH funding of Dr. Liau have played a direct and crucial role in murcidencel. Together with Merck, NIH is funding the murcidencel doses going into arms TODAY in a study investigating its efficacy in combo with pembrolizumab.

[biosectinvestor]

Your statements here are not correct but I do not have the time to spend with you to provide the full picture.